Last reviewed · How we verify
NCT05641532
Physical Activity in Persons Newly Diagnosed With Multiple Sclerosis
NA trial testing Physical activity behavioral intervention in persons newly diagnosed with MS in Multiple Sclerosis (MS) in 16 participants. Completed in 8 August 2023.
8 August 2023
Quick facts
| Lead sponsor | University of Alabama at Birmingham |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 16 |
| Start date | 17 January 2023 |
| Primary completion | 8 August 2023 |
| Estimated completion | 8 August 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Physical activity behavioral intervention in persons newly diagnosed with MS
Conditions studied
- Multiple Sclerosis (MS) — all drugs for Multiple Sclerosis (MS) →
Sponsor
University of Alabama at Birmingham
Who can join
18 and older, any sex, with Multiple Sclerosis (MS). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This single group pre-post pilot intervention will examine the feasibility and initial effect of a 12-week behavioral intervention, based on the Behavior Change Wheel and Capability-Opportunity-Motivation-Behavior (COM-B) model and remotely delivered through electronic newsletters and online one-on-one video conferencing, for promoting physical activity and secondarily reducing fatigue and quality of life in persons newly diagnosed with MS (diagnosed with MS within the past 2 years). The investigators hypothesize the proposed 12-week intervention will be feasible based on process, resource, management, and scientific outcomes. The investigators further hypothesize that individuals who receive the 12-week intervention will demonstrate an increase in physical activity behavior, particularly daily step counts, and reduce fatigue.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05641532
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Sclerosis (MS)
Currently open trials in the same condition.
- NCT07526493 — Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Media · Phase 1 · recruiting
- NCT06869278 — A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases · Phase 1 · recruiting
- NCT06053749 — An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimest · active not recruiting
- NCT06270641 — Increasing Physical Activity for Adults With Multiple Sclerosis (MS) · NA · recruiting
- NCT06157086 — Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France · active not recruiting
Other University of Alabama at Birmingham trials
Trials by the same sponsor.
- NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
- NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
- NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
- NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
- NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05641532 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
- Last refreshed: 16 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05641532.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing